. 2024 Jan 18;12(2):e03222-23. doi: 10.1128/spectrum.03222-23

TABLE 1.

Summary of HFIM dosing regimens, pharmacodynamic indices, and microbiological effect^a

Target C_max (μg/mL)^b	Infusion time (min)	1 hour C_max (μg/mL)	Frequency	Approximate human daily dose^c	%Time > MIC^d	Peak:MIC^d	AUC₂₄:MIC^d	ΔCFU^e_max	Day of growth recovery^f
15	Continuous	15.0	Continuous	20 mg/kg	100.0	1.9	45.0	−4.58	6.2
20.3	30	18.1	q12h	10 mg/kg	36.2	2.3	21.8	−3.71	5.7
22.3	30	19.9	q12h	12 mg/kg	40.0	2.5	24.0	−4.03	7.5
23.3	60	23.3	q12h	15 mg/kg	44.7	2.9	26.5	−4.57	7.0
50.5	30	45.0	q12h	25 mg/kg	70.0	5.6	54.0	−3.40	6.4
12.6	30	11.2	q24h	3.5 mg/kg	9.0	1.4	7.2	−1.87	4.4
40.1	30	35.7	q24h	10 mg/kg	30.8	4.5	22.9	−2.11	2.7
45.7	30	40.7	q24h	12 mg/kg	33.2	5.1	26.1	−2.41	3.8
52.5	60	52.5	q24h	15 mg/kg	37.5	6.6	31.7	−3.21	4.6
71.2	30	63.4	TIW^g	20 mg/kg	17.7	7.9	18.1	−2.14	1.7
149.6	30	133.3	TIW	40 mg/kg	23.5	16.7	38.1	−2.83	5.1
90	30	80.2	q7 days	25 mg/kg	6.5	10.0	7.4	−2.21	3.0

^{^a}

Notes: HFIM conditions modeled a half-life of 3 hours in all experiments.

^{^b}

Target C_max is defined as the free amikacin concentration at the end of amikacin infusion.

^{^c}

Approximate human daily dose that corresponds with the targeted 1 hour C_max based on our Pmetrics model using pediatric dosing.

^{^d}

For all indices, an MIC value of 8 μg/mL was used.

^{^e}

ΔCFU_max is the maximum decrease in CFU compared to control samples obtained at the same time.

^{^f}

Day of growth recovery is the day that CFU had rebounded by 1 log₁₀ above CFU_min in a treatment arm, linearly interpolated from the surroundings days when CFU samples were collected.

^{^g}

TIW, three times weekly.